J.W. Cole Advisors Inc. Purchases 17,653 Shares of Novo Nordisk A/S $NVO

J.W. Cole Advisors Inc. increased its position in Novo Nordisk A/S (NYSE:NVO) by 103.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 34,691 shares of the company’s stock after purchasing an additional 17,653 shares during the quarter. J.W. Cole Advisors Inc.’s holdings in Novo Nordisk A/S were worth $1,685,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of NVO. Godfrey Financial Associates Inc. bought a new position in Novo Nordisk A/S in the fourth quarter worth $25,000. WealthCollab LLC lifted its position in Novo Nordisk A/S by 93.5% in the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock worth $27,000 after purchasing an additional 260 shares during the period. American National Bank & Trust bought a new position in Novo Nordisk A/S in the fourth quarter worth $28,000. Maseco LLP bought a new position in Novo Nordisk A/S in the fourth quarter worth $29,000. Finally, Jackson Grant Investment Advisers Inc. bought a new position in Novo Nordisk A/S in the fourth quarter worth $29,000. 11.54% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts recently commented on NVO shares. Zacks Research raised Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 10th. Wall Street Zen raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Saturday, May 16th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Tuesday, February 24th. Jefferies Financial Group upgraded Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research note on Thursday, February 12th. Finally, The Goldman Sachs Group reiterated a “neutral” rating and set a $41.00 price objective (down from $63.00) on shares of Novo Nordisk A/S in a research note on Monday, March 2nd. Four equities research analysts have rated the stock with a Buy rating, eighteen have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $65.56.

Novo Nordisk A/S Stock Performance

Novo Nordisk A/S stock opened at $41.05 on Tuesday. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56. The stock has a fifty day moving average price of $41.71 and a two-hundred day moving average price of $46.12. Novo Nordisk A/S has a 52-week low of $35.12 and a 52-week high of $81.44. The firm has a market capitalization of $183.31 billion, a P/E ratio of 9.64, a P/E/G ratio of 3.83 and a beta of 0.78.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.The firm had revenue of $10.85 billion during the quarter. As a group, analysts anticipate that Novo Nordisk A/S will post 3.46 EPS for the current fiscal year.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk said its oral Wegovy pill has surpassed 3 million U.S. prescriptions in just over five months, suggesting very strong adoption and broadening use among patients who had not previously taken a GLP-1 drug.
• Positive Sentiment: Real-world data reportedly show Ozempic 2 mg performing competitively against Eli Lilly’s Mounjaro on glucose control and weight-loss outcomes, which supports Novo’s diabetes franchise. Article: Novo Nordisk Real-World Data Supports Ozempic Against LLY’s Mounjaro
• Positive Sentiment: Novo also highlighted investigational zenagamtide data showing 14.6% weight loss in adults with type 2 diabetes, reinforcing optimism around its pipeline. Article: Novo Nordisk’s Investigational Zenagamtide Shows 14.6% Weight Loss In Adults With Type-2 Diabetes
• Positive Sentiment: The company continues its share repurchase program, which can help support earnings per share and signals management confidence. Article: Novo Nordisk A/S – share repurchase programme
• Neutral Sentiment: Several articles framed Novo and Lilly as locked in a major race for the GLP-1 pill market ahead of Medicare coverage decisions, underscoring the long-term opportunity but also the competitive risk. Article: Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage
• Negative Sentiment: Eli Lilly’s oral GLP-1 pill reportedly outperformed rival therapies in late-stage diabetes trials, highlighting the competitive threat facing Novo Nordisk. Article: LLY Stock Climbs As Oral GLP-1 Pill Beats Novo Nordisk, AstraZeneca’s Therapies In Diabetes Trials
• Negative Sentiment: Investors also appeared disappointed that Novo’s ADA conference updates did not materially improve the company’s near-term competitive outlook, contributing to the stock’s weakness. Article: Novo Nordisk shares retreat after ADA conference updates fail to excite investors (NVO)

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.